A new report from the National Academies of Sciences, Engineering, and Medicine recommends steps U.S. communities can take to better measure their progress in building resilience to disasters, including measuring resilience around multiple dimensions of a community, and incentivizing the measurement of resilience.

Current evidence supports the classification of the contemporary red wolf as a distinct species of wolf, although additional genomic evidence from historic wolf specimens could change that assessment, says Evaluating the Taxonomic Status of the Mexican Gray Wolf and the Red Wolf, a new report from the National Academies of Sciences, Engineering, and Medicine.

Urban flooding is a complex and distinct kind of flooding, compounded by land use and high population density, and it requires a different approach to assess and manage, says Framing the Challenge of Urban Flooding in the United States, a new report from the National Academies of Sciences, Engineering, and Medicine.

A new report from the National Academies of Sciences, Engineering, and Medicine examines the effects and efficacy of using dispersants in marine oil spill response.

While computational reproducibility in scientific research is generally expected when the original data and code are available, lack of ability to replicate a previous study -- or obtain consistent results looking at the same scientific question but with different data -- is more nuanced and occasionally can aid in the process of scientific discovery, says a new congressionally mandated report from the National Academies of Sciences, Engineering, and Medicine.

The U.S. Department of Veterans Affairs (VA) should expand the requirement in its disability compensation process regarding who can diagnose traumatic brain injury (TBI) to include any health care professional with pertinent and ongoing brain injury training and experience, says a new congressionally mandated report from the National Academies of Sciences, Engineering, and Medicine.

A new report from the National Academies of Sciences, Engineering, and Medicine offers guidance to the Consumer Product Safety Commission (CPSC) on how to conduct a hazard assessment of nonpolymeric, additive organohalogen flame retardants (OFRs), which are used in some consumer products.

The changes in brain structure and connectivity that occur between the ages of 10 and 25 present adolescents with unique opportunities for positive, life-shaping development, and for recovering from past adversity, says a new report from the National Academies of Sciences, Engineering, and Medicine.

A centralized, consistently reported system of indicators of educational equity is needed to bring attention to disparities in the U.S. education system, says a new report by the National Academies of Sciences, Engineering, and Medicine.

Current cancer control efforts in the United States typically are fragmented and uncoordinated, but taking a systems approach to establish a U.S. National Cancer Control Plan would address the challenge more holistically, says a new report from the National Academies of Sciences, Engineering, and Medicine.

The nation’s highways and roads connect almost 330 million Americans and are important to both commerce and national security. Two-thirds of total passenger travel in the country moves along this vast network of roads, as does 60 percent of the weight and almost three-quarters of the value of total U.S. freight transported.

The U.S. Department of Defense’s Military Family Readiness System (MFRS) — a network of agencies, programs, services, and individuals that promotes the well-being and quality of life of military service members and their families — lacks a comprehensive, coordinated framework to support well-being, resilience, and readiness, says a new report from the National Academies of Sciences, Engineering, and Medicine.

The lack of supportive policies for families in the United States, such as paid parental leave, has serious implications for health equity, as it affects families’ overall health and financial stability, says a new report from the National Academies of Sciences, Engineering, and Medicine.

The National Academies today released Criteria for Selecting the Leading Health Indicators for Healthy People 2030, the first of two reports that will help inform the development of Healthy People 2030 (HP2030).

A new report from the National Academies of Sciences, Engineering, and Medicine – which reviews a separate report by a federally funded laboratory that examines options for treating low-activity radioactive waste at the Hanford Nuclear Reservation -- is available for public comment until Oct. 31.

A new report from the National Academies of Sciences, Engineering, and Medicine calls for a comprehensive national agenda to improve mental, emotional, and behavioral (MEB) health in children and youth. Despite advances in research, rates of depression, suicide and self-harm among young people have been increasing.

Whether a patient has a safe place to live or healthy food to eat has an important influence on their health, but such nonmedical social needs have not traditionally been addressed in routine health care visits.

U.S. colleges and universities should take a more intentional, inclusive, and evidence-based approach to mentoring students in STEMM (science, technology, engineering, mathematics, and medicine) – a shift that could engage and help retain a broader group of students in these fields, says a new report from the National Academies of Sciences, Engineering, and Medicine.

A new report from the National Academies of Sciences, Engineering and Medicine finds that the U.S. Environmental Protection Agencys (EPA) approach to its ongoing Integrated Risk Information System (IRIS) assessment plan is appropriate for synthesizing the scientific evidence and quantifying estimates of inorganic arsenic toxicity.

Medicine regulatory authorities — including the U.S. Food and Drug Administration (FDA) — should strengthen cooperation with other countries’ regulators to ensure the quality, safety, and efficacy of medicines, says a new report from the National Academies of Sciences, Engineering, and Medicine.

The U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Health (OASH) should focus funding on holistic, evidence-based, population-wide adolescent health programs that consider adolescent risk-taking as normative, according to a new report from the National Academies of Sciences, Engineering, and Medicine.

For severe acute pain due to surgeries and medical conditions, there is a lack of guidance on the appropriate type, strength, and amount of opioid medication that clinicians should prescribe to patients, says a new report from the National Academies of Sciences, Engineering, and Medicine.

A new report from the National Academies of Sciences, Engineering, and Medicine recommends ways to make supply chains -- the systems that provide populations with critical goods and services, such as food and water, gasoline, and pharmaceuticals and medical supplies – more resilient in the face of hurricanes and other disasters, drawing upon lessons learned from the 2017 hurricanes Harvey, Irma, and Maria.

The goal of achieving universal health coverage by 2030 — one of the United Nations’ Sustainable Development Goals — necessitates that countries strengthen their food and drug regulatory systems as a whole, says a new report from the National Academies of Sciences, Engineering, and Medicine.

The National Academy of Sciences, in partnership with The Kavli Foundation and the Alfred P. Sloan Foundation, will host a symposium to consider the future of science in the U.S. and how it can best serve society in the 21st century.

A new report from the National Academies of Sciences, Engineering, and Medicine finds that there is no risk-free setting for giving birth, whether at home, in a birth center, or in a hospital.

A new report from the National Academies of Sciences, Engineering, and Medicine finds K-12 teachers face new expectations and more demands from policymakers, parents, students, and schools, including addressing changes in curriculum standards, the emergence of more explicit teaching goals, and shifts in what it means to support all students in their development.

A new report from the National Academies of Sciences, Engineering, and Medicine finds new and innovative approaches to dust control are needed at Owens Lake, California, to improve air quality, reduce water use, and preserve habitats.

Seniors who are experiencing social isolation or loneliness may face a higher risk of mortality, heart disease, and depression, says a new report from the National Academies of Sciences, Engineering, and Medicine. Despite the profound health consequences — and the associated costs — the health care system remains an underused partner in preventing, identifying, and intervening for social isolation and loneliness among adults over age 50.

Although less invasive and more evidence-based approaches are available for temporomandibular disorders (TMDs) – a set of 30 disorders that cause pain or malfunction in the jaw joint and muscles of the jaw – some dentists continue to rely on aggressive or costly procedures as a first-line treatment, says a new report from the National Academies of Sciences, Engineering, and Medicine.

“Reports & Events” is a monthly tip sheet for the news media that highlights selected meetings of interest and reports from the National Academies of Sciences, Engineering, and Medicine.

More than 9.6 million children — or 13 percent of all children in the U.S. — live in families with annual incomes below the poverty line, according to data from 2015. As closures and restrictions related to COVID-19 begin to impact the U.S. economy, it’s clear many more families will be receiving fewer paychecks and less income in the coming months, putting more children at risk of falling below the poverty line.

Over the next five years, the U.S. Department of Defense’s Biological Threat Reduction Program (BTRP) should encourage and be among co-leaders in the federal government’s development of an enduring interagency mechanism to address an array of biological threats – including natural disease outbreaks, accidental releases, and intentional attacks -- to deployed U.S. forces and to the nation itself, says a new report from the National Academies of Sciences, Engineering, and Medicine

“Reports & Events” is a monthly tip sheet for the news media that highlights selected meetings of interest and reports from the National Academies of Sciences, Engineering, and Medicine.

The U.S. Department of Energy’s plan to dilute and dispose of 34 metric tons of surplus plutonium in the Waste Isolation Pilot Plant (WIPP) in New Mexico is technically viable, provided that the plan’s implementation challenges and system vulnerabilities are resolved.

A new report by research company

Maurice Jackson of Proven and Probable discusses the latest news from Millrock Resources with the company's CEO.

Visit the aureport.com for more information and for a free newsletter

President Trump speaks at the White House Friday. He is replacing an official who issued a report that found testing delays and equipment shortages at hospitals.; Credit: Jim Watson/AFP via Getty Images

President Trump is moving to replace the Department of Health and Human Services watchdog whose office found severe shortages of medical supplies in hospitals as COVID-19 cases surged.

In a Friday night announcement, the White House named Jason Weida as its nominee to take the permanent inspector general post currently occupied by Christi Grimm, who's been in that role in an acting capacity since January.

A longtime staffer with Health and Human Services, Grimm was leading the inspector general's office in April when it issued a report chronicling testing delays — up to seven days in some cases — as well as severe shortages of supplies in hospitals amid the COVID-19 pandemic.

"Hospitals reported that they were unable to keep up with COVID-19 testing demands because they lacked complete kits and/or the individual components and supplies needed to complete tests," the survey of 323 hospitals found. "When patient stays were extended while awaiting test results, this strained bed availability, personal protective equipment (PPE) supplies, and staffing."

The report also recalled how one hospital had even resorted to making its own disinfectant.

Trump reacted to the report by calling its findings "wrong," asking to know the name of the inspector general and suggesting the report was politically motivated. He later took to Twitter to castigate Grimm and the report even further.

"Why didn't the I.G., who spent 8 years with the Obama Administration (Did she Report on the failed H1N1 Swine Flu debacle where 17,000 people died?), want to talk to the Admirals, Generals, V.P. & others in charge, before doing her report. Another Fake Dossier!" Trump tweeted in early April.

Grimm is a career official, not a political appointee, and began serving in the Office of the Inspector General in 1999.

The nomination of Weida — currently an assistant U.S. attorney — marks the latest replacement of a high-level watchdog by the president. A month ago, he fired the inspector general who raised concerns that eventually led to his impeachment. Days later, he removed the inspector general charged with overseeing the government's coronavirus response bill.

Sen. Patty Murray, ranking Democrat on the Health, Education, Labor and Pensions Committee, said that Trump's nominee "must not get through the Senate without ironclad commitments" to continue the agency's current investigations without political interference.

"We all know the President hasn't told people the truth about this virus or his Administration's response, and late last night, he moved to silence an independent government official who did," Murray said in a statement released on Saturday. "Anyone who demands less will be complicit in the President's clear pattern of retaliation against those who tell the truth."

Health and Human Services did not comment to NPR on Grimm's future role, but said in statement that the agency had been preparing "to assist a new Inspector General appointee over a year ago, when the previous presidentially-appointed and senate-confirmed Inspector General first announced his intention to retire from government service. We will continue to work conscientiously to support a smooth leadership transition."

This content is from Southern California Public Radio. View the original story at SCPR.org.

; Credit: Illustration: Dan Carino

Read the full article at LAist

; Credit: Fanatic Studio/Gary Waters/Science Photo Library/Getty Images

There has been a rise in the number of minors contacting the National Sexual Assault Hotline to report abuse. That's according to RAINN, the Rape, Abuse and Incest National Network, which runs the hotline.

By the end of March, with much of the country under lockdown, there was a 22% increase in monthly calls from people younger than 18, and half of all incoming contacts were from minors. That's a first in RAINN's history, Camille Cooper, the organization's vice president of public policy, tells NPR.

Of those young people who contacted the hotline in March, 67% identified their perpetrator as a family member and 79% said they were currently living with that perpetrator. In 1 out of 5 cases where the minor was living with their abuser, RAINN assisted the minor in immediately contacting police.

"As a result of looking at the information that we had from those sessions, it was clear that the abuse was escalating in both frequency and severity," Cooper says. "So a lot of the kids that were coming to the hotline were feeling pretty vulnerable and traumatized. And it was a direct result of COVID-19, because they were quarantined with their abuser. The abuser was now abusing them on a daily basis."

Lockdown orders are first and foremost public health and safety measures. But statistically speaking, home is not the safest place for every young person. RAINN reports that about 34% of child sexual abusers are family members. Closing schools and canceling youth activities like sports removes children from the watchful eyes of "mandatory reporters" — those trusted adults, like teachers, nurses and child care providers, who are required by law in most states to report suspicions of child abuse or neglect.

However, Cooper says her organization has confirmed with authorities around the country that the child welfare system is still operating during the pandemic. That is, an official report of current and ongoing abuse will still trigger an investigation, and, if necessary, a child will be removed from the home.

"[Child welfare workers] will be coming to the home in person and proceeding with a formal investigation and a child forensic interview and things like that," she says. If the abuse is farther in the past and the child is not quarantined with the accused, Cooper says, the interview may take place over video chat.

In the meantime, RAINN and other child welfare organizations are lobbying to make it easier for children to report abuse. Cooper says, "One of the solutions we came up with that we are now currently working directly with the leadership in Congress on is to get all of the online learning platforms that children are interacting with to have a reporting function on that platform in plain sight for children."

This content is from Southern California Public Radio. View the original story at SCPR.org.

Maurice Jackson of Proven and Probable discusses the latest news from Millrock Resources with the company's CEO.

The median loss to fraudulent schemes that exploit the global health crisis is almost US$600

The post Americans report US$13 million in losses from coronavirus scams appeared first on WeLiveSecurity

A view of the Q1 2020 threat landscape as seen by ESET telemetry and from the perspective of ESET threat detection and research experts

The post ESET Threat Report appeared first on WeLiveSecurity

Source: Streetwise Reports   04/22/2020

In an April 20 research note, Dawson James analyst Jason Kolbert wrote that results from Can-Fite BioPharma Ltd.'s (CANF:NYSE.MKT) Phase 2 trial of Namodenoson for nonalcoholic fatty liver disease with or without nonalcoholic steatohepatitis "look pretty good."

He added that "the consistency of the data from the studies (preclinical and clinical), should support business development interest."

Dawson James has a $9 per share target price on Can-Fite; the stock is currently trading at around $1.75 per share.

Kolbert recapped the study design and provided the results.

This purpose of this multicenter, randomized, double-blinded, placebo-controlled trial involving 60 patients was to determine dose efficacy and safety. Patients were treated twice a day with either 12.5 milligrams or 25 milligrams of oral Namodenoson or a placebo for 12 weeks.

The primary endpoint was effect on inflammation, measured by mean percent change from baseline in alanine transaminase blood levels and safety. The second endpoints included the percent change from baseline in liver fat, as determined by MRI proton density fat fraction.

In terms of safety, study participants tolerated Namodenoson at both doses, and no adverse events were reported. Otitis media occurred in two patients but was deemed to be unrelated to the drug. The four other events that occurred that were drug related were mild and self-limited.

Regarding efficacy of Namodenoson, Kolbert noted that "for a small Phase 2 exploratory study, there appears to be a significant efficacy signal."

Kolbert provided updates on other Can-Fite clinical trials.

The company's COVID-19 trial is now designed. Plans call for it to be randomized, open label, and double armed with Piclidenoson administered plus standard supportive care, compared to standard supportive care alone, in 40 hospitalized COVID-19-infected patients with moderate to severe symptomatic disease.

Patients are to be randomized at a 1:1 ratio to one of the trial arms and treated for up to four weeks. The primary efficacy measures will be time to resolution of viral shedding, time to resolution of clinical symptoms, respiratory function, need for ventilatory support and overall mortality.

Piclidenoson, Can-Fite's lead drug candidate, also is in Phase 3 in two indications: moderate to severe rheumatoid arthritis (the ACROBAT study) and moderate to severe plaque psoriasis (the COMFORT study). Enrollment for both trials is more halfway complete. In both, Piclidenoson "hold great promise as alternative therapies with what appears to be a more favorable side effects profile," Kolbert commented.

Dawson James has a Buy rating on Can-Fite BioPharma.

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

Disclosures for Dawson James Securities, Can-Fite BioPharma Ltd., April 20, 2020,

Analyst Certification: The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

( Companies Mentioned: CANF:NYSE.MKT, )

Source: Streetwise Reports   04/24/2020

Mesoblast Ltd. (MESO:NASDAQ; MSB:ASX) today announced that it had achieved an "83% survival in ventilator-dependent COVID-19 patients (10/12) with moderate/severe acute respiratory distress syndrome (ARDS) treated during the period March-April 2020 with two intravenous infusions of Mesoblast's allogeneic mesenchymal stem cell product candidate remestemcel-L within the first five days." The company stated that of the 12 patients treated, 75% (9/12) successfully came off ventilator support after a median timeframe of 10 days. The firm advised that all of the patients were treated under an emergency Investigational New Drug (IDA) application or expanded access protocol at Mt. Sinai hospital in New York City and so far seven of the patients have been discharged from the hospital. The company noted that each of the patients had received a variety of experimental agents prior to being treated with remestemcel-L.

The firm explained that until now only about 9% (38/445) of ventilator-dependent COVID-19 patients at a major referral hospital network in New York City were able to come off ventilator support when treated with existing standard of care treatments during March and April 2020. The company reported that at a second major referral hospital network in New York City over the same period, there was 88% mortality with only 12% survival (38/320) among ventilator-dependent COVID-19 patients.

The company's CEO Dr. Silviu Itescu commented, "The remarkable clinical outcomes in these critically ill patients continue to underscore the potential benefits of remestemcel-L as an anti-inflammatory agent in cytokine release syndromes associated with high mortality, including acute graft versus host disease and COVID-19 ARDS. We intend to rapidly complete the randomized, placebo-controlled Phase 2/3 trial in COVID-19 ARDS patients to rigorously confirm that remestemcel-L improves survival in these critically ill patients."

Dr. Fred Grossman, Mesoblast's Chief Medical Officer, added, "There is a significant need to improve the dismal survival outcomes in COVID-19 patients who progress to ARDS and require ventilators. We have implemented robust statistical analyses in our Phase 2/3 trial as recommended by the US Food and Drug Administration (FDA) in order to maximize our ability to evaluate whether remestemcel-L provides a survival benefit in moderate/severe COVID-19 ARDS."

Mesoblast Ltd. is headquartered in Melbourne, Australia, and is a developer of industrial-scale, cryopreserved, off-the-shelf allogeneic cellular medicines. The company utilizes its proprietary mesenchymal lineage cell therapy technology platform in order to create a wide portfolio of commercial products and late-stage product candidates. The firm indicated that "the Biologics License Application to seek approval of its product candidate RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease has been accepted for priority review by the U.S. Food and Drug Administration." The company has offices in Australia, the U.S. and Singapore.

Mesoblast began the day with a market capitalization of around $687.9 million with approximately 106.7 million shares outstanding. MESO shares opened nearly 142% higher today at $15.59 (+$9.14, +141.71%) over yesterday's $6.45 closing price and reached a new 52-week high price this morning of $20.57. The stock has traded today between $13.01 and $20.57 per share and is presently trading at $14.76 (+$8.30, +128.76%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: MESO:NASDAQ; MSB:ASX, )

Shares of Kraton Corp. traded 24% higher after the specialty polymers and high-value biobased products maker reported that net income in Q1/20 increased to $209.0 million, compared to $13.6 million in Q1/19.

Shares of ION Geophysical traded higher after the company reported Q1/20 financial results that included a 53% year-over-year increase in revenue.